LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
MRKR
Marker Therapeutics, Inc.
There isn't enough reported data to score MRKR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MRKR Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
MRKR's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MRKR PE Valuation
MRKR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MRKR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect MRKR's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MRKR on earnings quality, reporting a profit while its opponent remains loss making.
MRKR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.47 | +$0.89 |
| Q1 2026 | -$0.67 | +$0.65 |
| Q4 2025 | -$0.91 | +$0.28 |
| Q3 2025 | -$1.22 | -$0.12 |
| Q2 2025 | -$1.36 | -$0.18 |
| Q1 2025 | -$1.32 | -$0.68 |
| Q4 2024 | -$1.19 | -$0.25 |
| Q3 2024 | -$1.10 | $0.00 |
MRKR is still losing money, but far less than before: $0.47 per share over the past year, against $70.80 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
MRKR has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus up 115% for MRKR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
MRKR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $751.7K | +115% |
| Q4 2025 | $1.1M | -51% |
| Q3 2025 | $1.2M | -36% |
| Q2 2025 | $861.2K | -26% |
| Q1 2025 | $349.1K | -72% |
| Q4 2024 | $2.3M | +113% |
| Q3 2024 | $1.9M | +648% |
| Q2 2024 | $1.2M | +53% |
MRKR's revenue is recovering but still below its 2023 peak: $751,691 last quarter, up 115% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -542% | +778 points |
| Q4 2025 | -171% | +0.7 points |
| Q3 2025 | -173% | -49 points |
| Q2 2025 | -495% | -297 points |
| Q1 2025 | -1320% | -1115 points |
| Q4 2024 | -171% | +107 points |
| Q3 2024 | -125% | +1118 points |
| Q2 2024 | -197% | +345 points |
MRKR's operating margin was −542% last quarter, up 778 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MRKR on cash generation, producing positive trailing cash flow while its opponent burns cash.
MRKR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.7M | -$1.8M |
| Q1 2026 | -$1.4M | +$4.1M |
| Q4 2025 | -$1.9M | +$2.8M |
| Q3 2025 | -$2.7M | -328% |
| Q2 2025 | -$1.9M | +$1.7M |
| Q1 2025 | -$5.5M | -$1.7M |
| Q4 2024 | -$4.7M | -$2.3M |
| Q3 2024 | $1.2M | +$2.3M |
MRKR has burned cash in almost every quarter: −$10M over the past year, against −$11M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MRKR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MRKR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +38% | +5.4M shares |
| 3 years | +120% | +10.5M shares |
| 5 years | +133% | +11M shares |
| Available history | +323% | +14.7M shares |
MRKR has 19M diluted shares, up 38% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MRKR Net Leverage
MRKR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MRKR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.7 | Neutral |
| Stochastic | 7.4 | Oversold |
MRKR's weekly RSI is 37 (neutral) and its Stochastic is 7 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MRKR PE vs Healthcare Sector
MRKR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MRKR on trend strength, trading above more of its moving averages.
MRKR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.99 | 9.1% below |
| 20 week MA | $1.16 | 22% below |
| 50 week MA | $1.36 | 34% below |
| 100 week MA | $1.42 | 37% below |
| 200 week MA | $2.53 | 64% below |
MRKR is in a downtrend: it's below all five of its weekly moving averages, and 64% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MRKR on returns for 2026, with the stronger performance.
MRKR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.7 | $15.3 | -50% |
| 2021 | $15.3 | $9.98 | -35% |
| 2022 | $9.98 | $2.60 | -74% |
| 2023 | $2.60 | $5.50 | +112% |
| 2024 | $5.50 | $3.49 | -37% |
| 2025 | $3.49 | $1.44 | -59% |
| 2026 YTD | $1.44 | $0.90 | -38% |
MRKR's yearly returns have swung widely, from +112% in 2023 to −74% in 2022. It's down 38% so far in 2026.